PDF(Pubmed)
Abstract：
BACKGROUND: Polyadenosine 5\'-diphosphoribose polymerase inhibitors (PARP-Is) are novel, effective agents for treating newly diagnosed epithelial ovarian cancer (EOC). However, the effect of PARP-I on the progression of recurrent EOC has not yet been determined. In particular, there is limited evidence regarding retreatment with PARP-I for recurrent EOC that has progressed on PARP-I in the short term.
METHODS: A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.
CONCLUSIONS: Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.
METHODS: A 69-year-old woman with a BRCA1 mutated EOC relapsed five months after starting olaparib maintenance following neoadjuvant chemotherapy and interval debulking surgery. Although the platinum-free interval was within six months, secondary cytoreductive surgery was performed because the tumor was locoregional. Following two cycles of weekly nedaplatin, niraparib induced a complete response, and the patient maintained a progression-free status for 15 months.
CONCLUSIONS: Even with short-term progression on PARP-I, local control combined with different platinum agents and PARP-I can be used to achieve good responses.
摘要：
背景：聚腺苷5'-二磷酸核糖聚合酶抑制剂（PARP-Is）是新的，治疗新诊断的上皮性卵巢癌（EOC）的有效药物。然而,PARP-I对复发性EOC进展的影响尚未确定.特别是,关于PARP-I治疗复发EOC的证据有限,但PARP-I治疗短期内进展.
方法：一名患有BRCA1突变EOC的69岁女性，在新辅助化疗和间隔减积手术后开始奥拉帕尼维持治疗5个月后复发。尽管无铂间隔在六个月内，因为肿瘤是局部的,所以进行了二次细胞减灭术.在每周两次奈达铂治疗后，尼拉帕利诱导完全反应，患者维持无进展状态15个月.
结论：即使PARP-I有短期进展，局部控制联合不同铂类药物和PARP-I可以达到良好的反应。
方法：一名患有BRCA1突变EOC的69岁女性，在新辅助化疗和间隔减积手术后开始奥拉帕尼维持治疗5个月后复发。尽管无铂间隔在六个月内，因为肿瘤是局部的,所以进行了二次细胞减灭术.在每周两次奈达铂治疗后，尼拉帕利诱导完全反应，患者维持无进展状态15个月.
结论：即使PARP-I有短期进展，局部控制联合不同铂类药物和PARP-I可以达到良好的反应。
